Eloise McLennan

Milton Keynes

Editor at Deep Dive

Editor at Pharmaphorum

Featured in: Favicon

medicaldevice-network.com Favicon

verdict.co.uk Favicon

naval-technology.com Favicon

airforce-technology.com Favicon

army-technology.com Favicon

pharmaphorum.com Favicon

railway-technology.com Favicon

pharmaceutical-technology.com Favicon

designbuild-network.com Favicon

packaging-gateway.com + 7 more

Articles

Regulators vs weight loss ads: Time to rethink the rules?

1 month ago | pharmaphorum.com | Eloise McLennan

“Medicated weight loss isn’t cheating.” Since I first wrote about the rise of GLP-1 counterfeits online, I’ve been inundated with weight loss ads across YouTube, TikTok, Instagram, and Facebook. No matter how many I block or report, they keep coming. Certain companies seem particularly relentless. Their ads don’t explicitly name the drugs they prescribe, but they don’t need to.
Changing Faces: Pharma and biotech January 2025

1 month ago | pharmaphorum.com | Eloise McLennan

Skip to main content twitter linkedin facebook rss Welcome to the first edition of Changing Faces for 2025. January kicked off the year with a flurry of notable leadership transitions across the pharmaceutical and biotechnology sectors. Here is a detailed look at the latest hires and departures. End of an era at Takeda. After leading Japan's largest drugmaker for 11 years, Christophe Weber announced his planned departure from Takeda in June 2026. Weber, who has steered the pharmaceutical...
Deep Dive: Research and Development 2025

1 month ago | pharmaphorum.com | Eloise McLennan

Skip to main content twitter linkedin facebook rss Every breakthrough in medicine, every new treatment that changes lives, starts with research. In this R&D-focused edition of Deep Dive, we explore how researchers are navigating innovation in a period of political and regulatory uncertainty, finding creative ways to adapt and push scientific progress forward. One of the most controversial healthcare topics is vaccines. With challenges to inoculation schedules mounting in the US, we trace the...
Changing Faces: Pharma and biotech November-December 2024

Jan 17, 2025 | pharmaphorum.com | Eloise McLennan

Skip to main content twitter linkedin facebook rss Welcome to the last edition of Changing Faces for 2024. With the holiday season limiting the December announcements, we chose to combine our November and December editions to bring you a comprehensive overview of the most notable moves that closed out the year. Here is a detailed look at the hires and departures across the industry at the end of 2024. End of an era. Bruce Cozadd, co-founder and CEO of Jazz Pharmaceuticals, is planning to...
Deep Dive: AI 2024

Dec 5, 2024 | pharmaphorum.com | Eloise McLennan

In this issue, we delve into the transformative impact of AI on healthcare and pharma, featuring insights on key AI trends from the floor of Frontiers Health, the ongoing battle against drift, and the promise of biological software. Plus, we explore AI's role in drug discovery, commercialisation, and medical information, and take an in-depth look at why drugs fail.
Deep Dive: Patients & Partnerships 2024

Nov 5, 2024 | pharmaphorum.com | Eloise McLennan

IN THIS ISSUE: The 2024 US Presidential race is nearing its end, but what does that mean for pharma? Plus, we explore the crucial role of patient-reported outcomes in healthcare delivery and examine how empathy-driven design is transforming patient support materials, rare disease collaboration, and much more.
Investment outlook: Key takeaways from LSX USA

Oct 4, 2024 | pharmaphorum.com | Eloise McLennan

Investment and strategic partnerships are the lifeblood of innovation in healthcare, driving groundbreaking discoveries and accelerating the development of life-changing therapies. And so, it was no surprise that the 2024 LSX USA Congress in Boston attracted life sciences innovators and decision-makers from around the world, eager to explore the latest trends shaping the industry.
Mounjaro and Zepbound shortages over, declares FDA

Oct 3, 2024 | pharmaphorum.com | Eloise McLennan

The US Food and Drug Administration (FDA) has declared an end to the shortage of tirzepatide, the active ingredient in Eli Lilly’s popular weight loss medication Zepbound and diabetes drug Mounjaro. After months of high demand and supply constraints, this news marks a significant development for patients and healthcare providers who have faced limited access to the popular GLP-1 receptor agonist.
FDA approval give BMS an edge in NSCLC treatment

Oct 3, 2024 | pharmaphorum.com | Eloise McLennan

Bristol Myers Squibb (BMS) has secured another win for Opdivo(nivolumab), becoming the only FDA-approved PD-1 inhibitor for resectable non-small cell lung cancer NSCLC in both a neoadjuvant-only regimen and as part of a perioperative treatment regimen in the US. This approval covers the combination of neoadjuvant Opdivo with chemotherapy, followed by surgery and adjuvant Opdivo monotherapy, providing a treatment option that extends from initial diagnosis to post-surgical care.
Gilead strikes deal to expand HIV drug access in 120 countries

Oct 2, 2024 | pharmaphorum.com | Eloise McLennan

Gilead Sciences has taken a major step towards increasing global access to HIV prevention with the signing of royalty-free voluntary licensing agreements with six generic manufacturers, paving the way for increased production and distribution of lenacapavir, its long-acting HIV prevention medication, in 120 high-incidence and resource-limited countries. The announcement comes swiftly after the drug achieved significant milestones in two pivotal Phase 3 trials PURPOSE 1 and PURPOSE 2.